Market Overview:
The global urinary follicle stimulating hormone market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of infertility, rising awareness about assisted reproductive technology (ART) procedures, and technological advancements in the field of ART. Based on type, the global urinary follicle stimulating hormone market is segmented into 75IU, 150IU, and others. The 150IU segment is expected to account for the largest share of the market in 2018 owing to its high efficacy and growing demand for fertility treatments. Based on application, the global urinary follicle stimulating hormone market is segmented into infertility treatment and assisted reproductive technology (ART). The infertility treatment segment accounted for a larger share of the market in 2017 due to an increase in cases of infertility across all regions.
Product Definition:
Urinary Follicle Stimulating Hormone (uFSH) is a hormone that is produced by the pituitary gland. uFSH stimulates the growth of ovarian follicles and the production of eggs in women. It also stimulates sperm production in men.
75IU:
75IU, also known as Follicle Stimulating Hormone (FSH), is a peptide hormone produced by the pituitary gland in response to stimulation from the thyroid-stimulating hormone. It is responsible for triggering the release of eggs from ovaries and can be used as an indicator of ovarian function.
150IU:
150IU is a form of Follicle Stimulating Hormone (FSH). It is used as an ingredient in the preparation of luteinizing hormone-stimulating hormone (LH-RH) drugs. LH and FSH are two hormones that control the menstrual cycle.
Application Insights:
The infertility treatment segment dominated the global market in 2017. This is due to the rising number of patients seeking assisted reproductive technology for various reasons such as low sperm count, female factor or ovulation problems. In addition, there are several products available in the market for male fertility that stimulate GUSH and help improve semen quality and quantity. These factors are expected to drive demand over the forecast period.
The others application segment includes diabetes insipidus, goitre, hypogonadism and hypothalamic amenorrhea syndrome (HAS).
Regional Analysis:
North America dominated the global market in 2017. High prevalence of infertility and growing adoption of ART are some factors responsible for its largest share. In addition, increasing government funding for R&D activities pertaining to male fertility is also expected to drive the regional market over the forecast period. Europe followed North America in terms of revenue generation owing to high demand for Urinary Follicle Stimulating Hormone (UFSH) products from Germany, France, Italy and U.K.
Asia Pacific is anticipated to witness significant growth during the forecast period due to rising awareness regarding various treatment options available for infertility problems coupled with increasing disposable income levels in emerging economies such as India.
Growth Factors:
- Increasing incidence of infertility in both men and women
- Growing awareness about the benefits of urinary follicle stimulating hormone therapy
- Rising demand for assisted reproductive technologies (ART)
- Technological advancements in the field of fertility treatment
- Growing number of single people and couples opting for fertility treatments
Scope Of The Report
Report Attributes
Report Details
Report Title
Urinary Follicle Stimulating Hormone Market Research Report
By Type
75IU, 150IU, Others
By Application
Infertility Treatment, Assisted Reproductive Technology
By Companies
IBSA, Ferring, Livzon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
220
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Urinary Follicle Stimulating Hormone Market Report Segments:
The global Urinary Follicle Stimulating Hormone market is segmented on the basis of:
Types
75IU, 150IU, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Infertility Treatment, Assisted Reproductive Technology
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- IBSA
- Ferring
- Livzon
Highlights of The Urinary Follicle Stimulating Hormone Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 75IU
- 150IU
- Others
- By Application:
- Infertility Treatment
- Assisted Reproductive Technology
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Urinary Follicle Stimulating Hormone Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Urinary Follicle Stimulating Hormone (UFS) is a hormone that stimulates the production of follicles in the ovaries. UFS is used to treat infertility.
Some of the major companies in the urinary follicle stimulating hormone market are IBSA, Ferring, Livzon.
The urinary follicle stimulating hormone market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Urinary Follicle Stimulating Hormone Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Urinary Follicle Stimulating Hormone Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Urinary Follicle Stimulating Hormone Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Urinary Follicle Stimulating Hormone Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Urinary Follicle Stimulating Hormone Market Size & Forecast, 2020-2028
4.5.1 Urinary Follicle Stimulating Hormone Market Size and Y-o-Y Growth
4.5.2 Urinary Follicle Stimulating Hormone Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 75IU
5.2.2 150IU
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Infertility Treatment
6.2.2 Assisted Reproductive Technology
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Urinary Follicle Stimulating Hormone Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Urinary Follicle Stimulating Hormone Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 75IU
9.6.2 150IU
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Infertility Treatment
9.10.2 Assisted Reproductive Technology
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 75IU
10.6.2 150IU
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Infertility Treatment
10.10.2 Assisted Reproductive Technology
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 75IU
11.6.2 150IU
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Infertility Treatment
11.10.2 Assisted Reproductive Technology
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 75IU
12.6.2 150IU
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Infertility Treatment
12.10.2 Assisted Reproductive Technology
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 75IU
13.6.2 150IU
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Infertility Treatment
13.10.2 Assisted Reproductive Technology
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Urinary Follicle Stimulating Hormone Market: Competitive Dashboard
14.2 Global Urinary Follicle Stimulating Hormone Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 IBSA
14.3.2 Ferring
14.3.3 Livzon
